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Participants’ experiences of ketamine bladder syndrome (KBS): a qualitative study  
 
Abstract: 
 
Aim: To explore recreational ketamine users’ experiences of ketamine bladder syndrome 
(KBS) and related healthcare provision issues.  
 
Research problem/Literature Review: KBS is an emerging condition caused by chronic, 
recreational ketamine use, which can result in extensive, irreparable damage to the bladder 
and urinary tract. However, little is yet known about how patients are personally affected by 
the condition, their help seeking behaviour or experiences of related healthcare services.  
 
Methodology: A qualitative study, informed by Heideggerian hermeneutics was undertaken. 
Twelve participants affected by KBS were purposively recruited into the study from an NHS 
continence service and a drug support agency in South Wales, UK. Data were collected 
through recorded, semi-structured interviews and analysed using a three-step approach.  
 
Results: Participants were predominantly younger, poly-drug users and typically developed 
KBS following prolonged, habitual ketamine use. The effects of KBS were considerable and 
included incontinence, haematuria, profound abdominal pain and embarrassment and were 
exacerbated by delays in help seeking, disjointed medical care and on-going ketamine use, 
which was integral to the self-management of KBS pain.  
 
Conclusions: KBS has significant impact on those affected and can result in extensive, 
irreversible damage to the bladder and urinary tract. The condition, and its management, is 
further compounded by chronic poly-drug use, chaotic lifestyles and a range of complex, 
related co-morbidities, which require a collaborative, multi-disciplinary approach. 
Anderson’s behavioral model of health services use provides an appropriate framework for 
better understanding help seeking/avoidance behaviour in this cohort, which can help 
inform clinical practice.  
 
 
Funding / competing interests: 
The study was funded by the Research Investment Scheme (Major Award). The authors 
declare no conflicts of interest.  
 
 
 
BACKGROUND 
Ketamine is a dissociative drug used in anaesthesia, palliative pain care and veterinary   
medicine (Morgan and Curran, 2011). It is also used recreationally as a ‘club drug’, 
particularly among younger drug users and is now one of the most popular drugs among UK 
clubbers (Morgan and Curran, 2011). It is mainly snorted in powder form, generally 
consumed socially with other users and can cause hallucinations, out of body experiences 
and intense detachment from reality (referred to as ‘the k-hole’) (Muetzelfeldt et al., 2008). 
It is not thought to be addictive, but tolerance and dependence can develop over time. 
 
The aetiology is unclear, but when used regularly and in increasingly higher doses, ketamine 
can cause considerable and potentially irreversible damage to the bladder and urinary tract, 
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resulting in ulceration, fibrosis, bleeding, pain and incontinence (Mason et al., 2010). The 
condition is commonly known as ketamine bladder syndrome (KBS). The prevalence of KBS 
in the UK is unknown but, consistent with escalating ketamine use, is believed to be 
increasing. Survey data suggest that only around 10% of symptomatic recreational ketamine 
users actually seek medical help (Winstock et al., 2012) although it is unclear why. There is 
no curative treatment, although abstinence from ketamine may help reduce irritation and 
inflammation in some patients (Logan, 2011).  
 
To inform this study, a comprehensive literature review was undertaken using CINAHL, 
MEDLINE and PsychINFO databases. The following search terms were used, in various 
combinations: ketamine, bladder, syndrome, KBS, urinary, ulcerative and cystitis. Papers 
published in English were sought, no date restrictions were applied.  From around 2007 
onwards, there is an emerging programme of research in this area, although most relevant 
literature is in the form of medical case studies, reviews and discussion papers, which 
primarily highlight symptom effects and treatment challenges. No studies were found that 
specifically explored the personal experiences of those affected by KBS. 
 
Consequently, little is yet known about how patients are affected by KBS, their 
understanding of the condition, motivations for seeking help or their experiences of related 
healthcare services. An in-depth understanding of these complex issues could therefore 
help to inform related clinical practice. This study was subsequently undertaken to explore 
these multifaceted issues.  
 
METHODOLOGY 
 
Aim: 
To explore recreational ketamine users’ experiences of KBS and related healthcare provision 
issues.   
 
Methodology: 
To better understand participants’ experiences, a qualitative approach, informed by 
Heideggerian hermeneutics, was used. The methodology is interpretative and is therefore 
appropriate in helping to uncover common meanings in narratives and to comprehend 
situational contexts (Majdalani et al., 2014). The methodology allows participants to reflect 
on and describe their experiences and social practices, in depth, through ‘naturalistic 
conservations’, which help to reflect their lived experiences (Omeri and Atkins, 2002; 
Clayton et al., 2014).  
 
Sample and recruitment 
Participants were purposively recruited into the study in Spring-Autumn 2013 from a 
regional NHS continence service and a community based drug support agency in South 
Wales, UK. Participants were identified, approached and recruited into the study by 
gatekeepers in each organisation, using an agreed inclusion/exclusion criteria, which were 
developed in consultation with both centres. Respondents were invited to participate if they 
were adults, ketamine users, experiencing KBS and able to provide informed consent. 
Respondents were not invited to participate if they were legal minors, unable to provide 
informed consent, diagnosed with other bladder problems (e.g. pre-existing bladder 
problems and/or other urological conditions, not related to ketamine use) or unaware of 
their condition. 
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Suitable participants were provided with a participant information pack, which included a 
covering letter, participant information leaflet, expression of interest form (EOI) and 
freepost envelope. Those interested in the study completed an EOI form and returned it to 
the research team. The project research assistant (RA), who was not involved in their 
treatment or care, then contacted prospective participants to discuss the study in more 
detail, answer any questions and, if appropriate, arranged to meet. On meeting, the RA 
ensured they met the inclusion criteria and, if they were happy to participate, written 
consent was obtained prior to data collection. 
 
Twelve participants (7 men, 5 women) were recruited into the study. Participants’ mean age 
was 26 years (age range 20-43 years). At the time of recruitment, all were poly-drug users, 
most were unemployed, one was in part-time training, one was self-employed and two 
were employed part-time. Further participant demographics are presented in table 1: 
 
Table 1. Participant demographics 
 
ID code Gender Estimated 
number of 
years using 
ketamine 
Estimated daily 
dose (grams) at 
peak usage 
F101 Female 6  Not specified  
M102 Male 7  2–8g 
F103 Female 11  1g  
M104 Male 10  Not specified 
F105 Female 11  8–10g  
M106 Male 8  50g (timeframe not 
specified) 
M107 Male 12  10-15g 
F108 Female 6  9g 
F109 Female <1 1g 
M110 Male 13  5g 
M111 Male 3  2g 
M112 Male 8 20g 
 
 
 
Data collection 
Data were collected through semi-structured interviews, which were conducted in private 
by the RA, at the drug support agency premises. Interviews lasted 30-60 minutes. The 
interview schedule was devised following a review of the literature and in discussion with 
gatekeepers at both recruiting organisations.  
 
Consistent with the espoused methodology, interview questions were open and provided a 
framework for discussion, while allowing participants to talk freely about their experiences 
of ketamine use, KBS and associated healthcare provision issues. To obtain an in-depth 
understanding of participants’ experiences, several techniques were used during the 
interview, as and where appropriate, including probing, clarifying, restating and 
summarising (Gill and Lowes, 2014).   
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To establish appropriateness, the interview schedule was piloted on the first three 
participants recruited. The schedule was found to be appropriate and not amended. All pilot 
data were therefore incorporated into the main study findings. 
 
Data analysis 
Interviews were digitally recorded, transcribed verbatim and analysed using Linsdeth and 
Norberg (2004) three-step approach, which involves naive reading, structural analysis and 
comprehensive understanding. In the first step (naive reading), interviews were listened to 
and interview transcripts were read and re-read with an ‘open mind’ to establish a sense of 
the collective data and to inform the next analysis stage. In the structural analysis phase, 
initial sub-themes and, subsequently, themes were identified and formulated that conveyed 
a sense of participants’ experience (Gill and Lowes, 2014). The final phase (comprehensive 
understanding) involved an in-depth interpretation of the data and reflection, revision and 
reconsideration of the themes identified during the analytical process (Gill and Lowes, 
2014).  
 
Data analysis was led by two researchers (CS and PG) but all phases were discussed critically 
within the research team, to further facilitate interpretation of the data. Data analysis was 
managed using Nvivo10.  
 
Ethics 
University and NHS Research Ethics Committee (REC) and R&D approvals were granted in 
Winter 2012/13. Written informed consent was obtained from all participants prior to 
interview. Participants were assured of anonymity and confidentiality and advised that they 
could pause or stop the interview and/or withdraw from the study at any time, without 
prejudice. To ensure anonymity and confidentiality, names have been replaced by a unique 
identification code, which indicates gender (M or F) and chronological order of recruitment 
(e.g. F101, M102). 
 
FINDINGS 
Four key themes were identified from analysis of the data: 
 Ketamine use and associated bladder symptoms 
 Pain experience and pain management 
 The psychosocial impact of KBS 
 Healthcare service experiences  
 
Ketamine use and associated bladder symptoms 
Most participants were introduced to ketamine in their teens by an older relative (e.g. 
brother) or friend and, at the time of initiation, were already poly-drug users. Ketamine was 
primarily snorted as a powder and generally consumed socially with friends. All maintained 
that they were initially unaware of the potentially adverse effects of ketamine on the 
bladder. However, as tolerance and dependence gradually increased, ketamine was used 
more frequently (often daily) and in increasingly higher doses, to gain the desired 
dissociative effect. Consequently, most participants developed noticeable KBS symptoms 
within around 6-24 months of this change in use.  
 
Common KBS symptoms included bladder storage or voiding problems, frequency, nocturia, 
urgency, hesitancy, urinating with interrupted flow, leakage, voiding small volumes of urine 
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and, in many, urge incontinence often occurred if they could not reach a toilet in time. Most 
symptoms were unpredictable, interchangeable, embarrassing and distressing. However, as 
they were insidious and common amongst other users, they became ‘an acceptable norm’. 
Nonetheless, some symptoms were more serious and of far greater concern. For example, 
urinary retention, requiring catheterisation and, eventually, intermittent self-
catheterisation: 
 
I was going a lot more, but when I was going, I wasn’t passing much and really bad 
burning and blood in my urine. Then just before my 18th birthday I was admitted 
because I couldn’t go to the toilet anymore. F108 
 
One of the latter KBS symptoms was haematuria, which was initially infrequent and 
relatively minor but gradually increased significantly, causing considerable concern: 
 
When I first noticed, I didn’t think nothing of it because it wasn’t hurting. It was just 
little strings of blood and then it was like just blood, there weren’t no urine in it.... It 
would be like clots, like pure blood... Within about six months, it was like nothing 
you’ve ever seen....  Every time I was weeing, it looked like a murder scene in my 
toilet. M106 
  
Pain experience and pain management 
One of the most progressive, profound KBS symptoms was pain, which was exacerbated by 
regular ketamine use. Pain was commonly experienced in the abdomen, supra-pubic, lower 
back and/or genital regions and was particularly severe when needing to urinate and/or 
when urinating. While the nature and intensity often varied, KBS pain was described as 
intense, cramping and was often unbearable: 
 
It felt like my vagina was on fire… like I was being torn apart. It got that excruciating 
my mum took me to hospital. I was in that much pain I was screaming... tell them to 
get some pain relief.  They were trying to ask me questions and I couldn’t answer 
because I was in absolute agony, it was worse than childbirth... it felt like somebody 
was slicing me open. F105 
 
Most participants lived with severe, chronic, debilitating pain, which was extremely difficult 
to manage, as most prescribed analgesia, including Tramadol, provided inadequate pain 
relief: 
 
There’s not much you can do about it, painkillers wouldn’t work, nothing would work, 
because the pain was like I’ve never experienced. M112 
 
Participants felt that most health professionals did not fully appreciate the severity of their 
pain, although they acknowledged that their chronic substance misuse probably affected 
General Practitioners (GP’s) analgesic prescribing practices. Consequently, self-medication 
was common: 
 
These last few days I’ve been taking stupid drugs that I’ve been buying off people, 
like prescribed medication they’re on, because nothing’s happening. I even bought a 
bottle of Oramorph off someone the other week. M104 
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Ketamine appeared to be the only drug that provided effective, short-term pain relief and it 
was therefore consumed regularly to manage pain. However, participants were aware that 
this further exacerbated their KBS. Many therefore felt hopelessly trapped in a perpetual 
destructive cycle of use, abuse and ongoing harm:  
 
I’m in pain constantly, I’ve been on/off Tramadol 2 years and it’s not working. I’ve 
been off ketamine for 7 months but Friday I went back to it because it’s the only thing 
that’s getting rid of the pain. The pain’s got to the stage where I can’t bear it, hence 
why I’ve started taking ketamine again and I didn’t think I ever would. I take it and 
then I’m in agony when it wears off. I don’t want to get back on that cycle, but it’s 
the only option I’ve got. No one seems to be listening and there’s nothing I can do for 
the pain. F108 
 
The psychosocial impact of KBS 
KBS had a considerable psychosocial impact on participants.  As symptoms worsened, most 
were reluctant to venture too far from the toilet, as they often needed to urinate urgently 
and frequently, which adversely affected their ability to leave the house, socialise and even 
work: 
 
I lost my job because I had to keep going to the toilet. I thought I can turn my life 
around because I’ve got a job. But where I kept going to the toilet every half hour, 
they let me go.... I still can’t use public transport because.... I have to get off after a 
five minute journey. M104 
 
Given the age of most participants, symptoms such as incontinence and haematuria, also 
caused considerable embarrassment and anxiety regarding their future health. Problems 
were further compounded by poly-drug dependency, which commonly resulted in 
disorganised lifestyles, insomnia, lethargy and depression. Furthermore, participants 
acknowledged the detrimental impact their problems had on loved ones and their ability to 
have meaningful relationships, as sexual intercourse was often too painful. 
 
Healthcare service experiences  
Participants were initially reluctant to seek medical help, as preliminary KBS symptoms were 
‘normalised’. Feelings of embarrassment and self-loathing were common and compounded 
by the fear of being stigmatised. The social nature of ketamine use also commonly resulted 
in ‘friend of a friend stories’ about painful, embarrassing medical procedures, which were 
off-putting. Some participants were also concerned that worsening symptoms were 
indicative of terminal illness: 
 
I was scared, I thought I was dying. I thought I was peeing out organs. I was too 
afraid to go to the Doctors in case he was going to tell me I had cancer, you’re dying. 
I didn’t want to know that, I’d rather not know and not have those worries.  M106 
 
The eventual triggers for seeking help were worsening symptoms (particularly incontinence, 
severe pain and haematuria) and pressure from family and friends. GP’s were generally the 
first point of contact, although subsequent A&E visits, following episodes of severe pain 
and/or heavy bleeding were common. However, during these initial consultations, not only 
were they not asked about ketamine use, despite presenting symptoms, but they also did 
not routinely volunteer such information, because they were too embarrassed to do so. 
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Even when they eventually did disclose ketamine use to their GP, the significance of such 
information was apparently not acknowledged.  
 
Misdiagnosis (e.g. urinary tract infections; UTIs) and repeated, unnecessary courses of 
antibiotics were therefore common and compounded the belief that GPs had a very limited 
understanding of KBS. It was only when symptoms did not resolve that participants were 
eventually referred to a urologist and subsequently diagnosed with KBS. Participants were 
commonly advised that, while no curative treatment was available, symptoms would 
probably eventually resolve if they stopped using ketamine. While this advice was 
considered appropriate, in and of itself, it was considered unhelpful, as participants required 
further dedicated help and support to quit:  
 
There needs to be specialist knowledge about drug misuse and you should be 
signposted straight away. The question should be asked of any person with bladder 
problems, have you ever used Ketamine? If they say yes, they should get referred to a 
drug service that’s got knowledge about it. [They say you have to stop it] but it’s like 
telling a kid to stop eating sweets. [It’s mentally addictive] and it helps with the pain 
too. M110 
 
Experiences of healthcare services varied. While some healthcare encounters were regarded 
as positive (e.g. where there was a good relationship with health professionals), most 
participants felt that they had largely been judged, blamed, ignored and treated with 
contempt by many health professionals. The provision of information and support about 
chronic ketamine use and KBS was also found to be limited. Furthermore, due to ‘chaotic 
lifestyles’, engagement with health professionals was problematic and clinic non-attendance 
was therefore common. 
 
DISCUSSION 
 
The impact of KBS  
KBS has a considerable impact on those affected. Frequency, nocturia, urge incontinence, 
incontinence, haematuria (Chu et al., 2007; Middela and Pearce, 2011; Wood et al., 2011) 
and debilitating pain are common. Analogous with the psychosocial effects of urinary 
incontinence (Shaw et al., 2008) and substance misuse (Macleod et al., 2004; Dutra et al., 
2008) more generally, this study demonstrates that feelings such as embarrassment, 
uncertainty, anxiety, guilt, self-loathing and depression are common and pervasive. The 
emotional impact is perhaps further compounded by participants’ relatively young age and 
the perceived self-inflicted nature of their condition. Advanced symptoms appear to result 
in behaviour modification, such as staying close to a toilet, which can subsequently 
contribute to social isolation. 
 
The long term consequences of KBS are unclear (Colebunders and Van Erps, 2008; Oxley et 
al., 2009; Mason et al., 2010) but are probably related to condition severity and duration of 
habitual ketamine use, especially if on-going. However, in advanced stages, damage to the 
bladder and urinary tract are likely to be extensive, intractable and potentially irreversible. 
Such patients, most of whom are relatively young, may therefore require several invasive 
procedures and treatments for symptomatic relief, and in severe cases, bladder 
reconstruction or cystectomy, which will usually require costly, lifetime follow-up (Cottrell 
and Gillatt, 2008; Raison et al., 2015). Other long-term effects of chronic ketamine use are 
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also poorly understood but can include lethargy, insomnia, impaired cognition, paranoia and 
psychosis (Morgan et al., 2004; Muetzelfeldt et al., 2008; Tackett-Gibson, 2008). These 
problems, particularly when combined with poly-drug use (which further obfuscates the 
disease process), are likely to contribute to the development of chaotic lifestyles and 
complex co-morbidities, which adversely affect quality of life and further complicate patient 
management.  
 
Complexity of KBS and chronic substance misuse 
Several factors related to chronic substance misuse compound the complexity of KBS and its 
management. Most chronic ketamine users are young poly-drug users (Muetzelfeldt et al., 
2008; Cheung et al., 2011; Winstock et al., 2012). While existing research indicates that 
habitual ketamine use causes KBS (Wood et al., 2011), it is possible that the condition 
and/or many of the associated problems are related to, or exacerbated by, poly-drug use.  
 
KBS pain is severe and very difficult to manage. However, because of chronic substance 
misuse problems, anecdotal evidence suggests that GP’s are reluctant to prescribe opiates. 
Self medication is therefore common, which is associated with significant risks, such as 
adverse side-effects and over-dosage. Ketamine is also instrumental in pain self-
management because of its short-term effectiveness. However, this practice not only causes 
further, potentially irreversible damage to the bladder and urinary tract but it also makes 
ketamine cessation extremely difficult. Furthermore, because of its dissociative effects, 
users commonly limit the potential for harm by consuming ketamine with other users, 
which results in the development of close drug-related friendships (Joe-Laidler and Hunt, 
2008; Riley et al., 2008). Consequently, these social networks further complicate ketamine 
cessation and probably compound feelings of hopelessness. 
 
Assessment and management of patients with KBS 
It is estimated that around 20-30% of chronic ketamine users will experience lower urinary 
tract symptoms (LUTS) (Shahani et al., 2007; Bhattacharya, 2011; Wood et al., 2011; 
Winstock et al., 2012), typically within 3-24 months of habitual ketamine use (Tsai et al., 
2009; Srirangam and Mercer, 2012; Jalil and Gupta, 2012). However, it is unclear what 
specifically triggers the condition (e.g. toxic thresholds) and/or whether it is exacerbated by 
other factors (e.g. gender and poly-drug use).  
 
Case study evidence indicates that symptoms, especially if mild to moderate, are potentially 
reversible following ketamine cessation (Cottrell and Gillatt, 2008; Cottrell et al., 2008; Ma, 
2008; Tsai et al., 2010; Cheung et al., 2011). Management is therefore dependent on timely 
diagnoses, specialist referral and ketamine cessation. However, appropriate management, 
particularly within primary care, appears to be problematic, as many GPs have a poor 
understanding of KBS and symptoms typically resemble UTIs and other LUTS (Logan, 2011; 
Srirangam and Mercer, 2012). Diagnosis is further complicated, due to the lack of 
appropriate questioning, and/or voluntary disclosure, regarding chronic ketamine use in 
presenting patients. Consequently, misdiagnosis, recurrent inappropriate treatments and 
significant delays in specialist referrals, of 12-18 months or more, are common, by which 
time many patients are likely to have advanced KBS and a range of other health-related 
problems that may require multi-agency input. 
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Help seeking and avoidance  
Delays in seeking medical attention can adversely affect disease progression and the 
development of more complex co-morbidities, which are usually more difficult and costly to 
treat. Identifying factors that affect help seeking behaviour can therefore help to inform the 
development of appropriate interventions that may promote expeditious access to relevant 
healthcare services. However, while help avoidance is common in KBS, particularly in the 
early stages, when the condition is potentially reversible, a meaningful rationale for this 
behaviour has not yet been adequately explicated. 
 
This study indicates that several factors inform help seeking/avoidance behaviour. The 
wider, related urinary incontinence and substance misuse literature, also respectively offer 
additional, constructive insights into these complex issues. Furthermore, Andersen’s 
behavioral model of health services use (Andersen 1995) provides an expedient framework 
for better understanding the fundamental components that commonly inform help 
avoidance/seeking in healthcare. The model was originally developed in 1968 (and has since 
undergone several iterations) to facilitate understanding of how relevant healthcare 
services are accessed and/or used (Babitsch et al., 2012). It has subsequently been applied 
in extensively many healthcare studies, including related substance misuse (Rapp et al., 
2006) and urological research and was therefore considered appropriate for this patient 
population. Andersen (1995) proposes that several key variables, notably, predisposing 
characteristics (e.g. demographics, social networks, and health beliefs), enabling/inhibiting 
factors (e.g. psychosocial issues and social support) and situational need (e.g. condition 
impact and problem recognition), interact to facilitate and/or impede healthcare use. 
 
Several predisposing characteristics appear to confound help seeking behaviour in this 
study. Analogous with the related urinary incontinence literature (Shaw et al., 2008, Wang 
et al., 2015), the relative young age of most participants and the general association of 
troublesome urinary symptoms, such as incontinence, with aging, are likely to be significant 
barriers to help seeking. Social networks are also problematic, as they largely consistent of 
other chronic ketamine users, many of whom, as Chu et al (2008) postulate, may also be 
symptomatic but not receiving treatment. Failing to see drug related problems as sufficient 
concerns are common amongst many habitual drug users and their social group (Rapp et al., 
2006). ‘Friend of a friend’ stories about embarrassing, painful urological procedures are also 
ubiquitous within these social networks and extremely off-putting. Furthermore, many 
chronic ketamine users remain somewhat ambivalent about the cause of and risks 
associated with KBS, which probably further compounds help avoidance.  
 
Numerous enabling/inhibiting factors also inform this process. The emotional impact of KBS 
is considerable. Consequently, as demonstrated within the wider, related literature, feelings 
such as embarrassment, self-loathing and fear of being stigmatised are known to be 
significant barriers to help seeking (Cunningham et al., 1993; Shaw et al., 2008, Cheung et 
al., 2011; Wang et al., 2015). The perception that ketamine is a ‘horse tranquiliser’ (Moore 
and Measham, 2008) may further exacerbate help avoidance because of concerns about 
particularly ‘deviant behaviour’. Synonymous with the wider substance misuse literature, 
unemployment and disorganised lifestyles are common and known to adversely affect help 
seeking and healthcare engagement (Friedmann et al., 2000, Rapp et al., 2006). However, 
the multifaceted nature of KBS, related to the inextricable amalgamation of ketamine/poly-
drug dependence and chronic bladder symptoms, probably further compound this problem. 
Furthermore, given the prevalence of additional, related co-morbidities in poly-drug users, 
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including potential mental health problems, help seeking is likely to be further complicated 
in this cohort. Finally, due to chaotic lifestyles and apparent social isolation, access to 
meaningful social support, which is integral to help seeking, is limited. However, subsequent 
pressure from family and friends, as a result of ongoing, worsening symptoms, appears to 
be a key help seeking facilitator. 
 
Establishing treatment necessity generally involves appraisal of several issues, such as 
symptom severity, perceived health risk, treatment effectiveness beliefs and readiness for 
treatment (Cunningham et al., 1994; Shaw et al., 2008). However, mild KBS symptoms are 
normalised and tolerated, probably because of their insidious nature and commonality 
amongst fellow ketamine users. Help avoidance is therefore common, when symptoms are 
regarded as inconsequential (Cunningham et al., 1993, Shaw et al., 2008, Cheung et al., 
2011). It is also likely that help seeking appraisal entails several considerations; notably, KBS 
symptoms, other complex co-morbidities and long-term substance misuse problems, which 
many may not yet be willing or able to meaningfully address. It is therefore unclear what the 
precise priorities are for help seeking in KBS, although the ‘tipping points’ appear to be 
prolonged, worsening symptoms, particularly pain, incontinence and haematuria, which 
adversely affect quality of life and are perceived as significant health threats. However, this 
typically occurs later in the condition, when damage to the bladder and urinary tract may be 
irreversible. These multifarious issues not only therefore highlight the complexity of help 
seeking in KBS but also the subsequent challenges faced by health professionals in 
developing suitable initiatives to help facilitate timely access to appropriate support 
services. 
 
IMPLICATIONS FOR PRACTICE AND RELATED RESEARCH 
Findings from this study indicate that Anderson’s behavioral model of health services use 
(Andersen, 1995) provides an appropriate theoretical framework for understanding the key 
facilitators and barriers to help seeking in KBS. However, as Andersen (1995) acknowledges, 
little is yet known about the primacy of individual determinants or the interactive effects of 
key variables (Rapp et al., 2006), although, given the nature of this qualitative study, these 
issues are beyond the scope of this research. The application of Andersen’s model is 
therefore not intended to provide a definitive exposition of these complex issues, but 
rather, it merely offers health professionals a useful framework for comprehending the 
complexities associated with help seeking, avoidance and engagement, which can 
subsequently help to inform clinical practice. In particular, it can help to facilitate the 
development of appropriate strategies to reduce and/or prevent harm, moderate help 
seeking obstacles and promote expedient approaches to patient management.  
 
Given the limited understanding of KBS amongst many health professionals, especially GPs, 
there is a need to raise awareness of the condition and approaches to management, 
through dissemination and training, so that clinicians are better able to treat and support 
patients. Effective harm prevention/reduction strategies are also required to better inform 
existing (and prospective) users about the harmful effects of chronic ketamine use. 
Information provision should emphasise the particularly undesirable effects of KBS, such as 
incontinence, haematuria and pain, which users are likely to find disconcerting. To help 
promote timely engagement with healthcare services, drug support agencies in particular, 
need to highlight the potential reversibility of symptoms when identified early.  
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Management of KBS should largely focus on minimising bladder damage through 
appropriate assessment, timely referral and abstinence from ketamine use. Health 
professionals should therefore ask patients presenting with severe, persistent and 
unresponsive LUTS about ketamine use (Cottrell and Gillatt, 2008; Mason et al., 2010; 
Jenyon and Sole, 2013; Srirangam and Mercer, 2012) in an appropriate, sensitive manner. 
This routine practice may also help to reduce embarrassment or stigma associated with 
ketamine use.  
 
As KBS is inexorably associated with poly-drug dependence, chronic bladder problems and a 
range of multifaceted, related co-morbidities, the condition should be considered as part of 
a more complex whole, the management of which is beyond any one professional group. 
Instead, a collaborative, multi-disciplinary approach is required, which involves nurses, GPs, 
urologists, pain and drug support teams. There is also a need for greater liaison between 
health and social care services (Winstock et al., 2012) to ensure a more integrated approach 
to the management of those with such complex needs. Clearly, the most important aspect 
of KBS management is early ketamine cessation and this must therefore be the key message 
that health professionals convey to patients (Logan, 2011; Morgan and Curran, 2011). 
However, because of its social nature, analgesic function and dependency issues, health 
professionals should acknowledge that KBS patients will require further specialist help and 
support to facilitate ketamine abstinence, as they are unlikely to achieve this by their own 
volition.  
 
Drug support agencies are best placed to advise in the management of drug dependency. 
However, findings suggest that substance misuse regimens are likely to be complex and 
costly, due to tolerance, dependence and ongoing poly-drug use and, therefore, to be 
effective, may even require removing the user from their current social network. An 
effective approach to pain management is also essential to help minimise the likelihood of 
continued ketamine use (and/or other drugs) for pain self-management. There is therefore 
a need for pain teams to advise nurses, GPs and urologists about appropriate pain 
management. Engaging poly-drug users in healthcare services is, however, an ongoing, 
obstinate problem and devising meaningful strategies to promote engagement remains a 
significant challenge that requires further work.  
   
This study has also highlighted several areas in need of further research that could further 
help inform practice and policy. These include the need for: 
 
 Accurate epidemiological data to establish the nature and extent of chronic 
ketamine use and KBS. 
 Research that better informs understanding of KBS aetiology and/or factors that may 
exacerbate disease progression.  
 Research that explores the perspectives of health professionals involved in treating 
this patient group, to better understand the challenges associated with KBS 
management. 
 
Study limitations 
While this study provides a novel, in-depth insight into participants’ experiences of KBS, 
there are several limitations associated with this research. Due to the size and nature of the 
sample, findings may not be representative of the wider KBS, or chronic ketamine user, 
population. During data collection, it was also apparent that some participants struggled 
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with particular recall issues, such as ketamine dose/frequency specificity. Consequently, the 
veracity of aspects of some accounts is perhaps questionable. It is also important to 
recognise that all participants were poly-drug users. Many of the issues raised, may not 
therefore be due to ketamine alone, but are perhaps instead related to the effects of 
chronic poly-substance misuse and/or other underlying co-morbidities. 
  
CONCLUSION  
This study demonstrates that KBS has a profound impact on those affected, commonly 
resulting in significant and potentially irreversible damage to the bladder and urinary tract. 
The condition is further compounded by ketamine and poly-drug dependence, related co-
morbidities and delays in help seeking, which further complicate patient management. 
Findings from this study also suggest that Anderson’s behavioral model of health services 
use (Andersen, 1995) provides a relevant framework for understanding help 
seeking/avoidance behaviour in this patient population, which can help inform clinical 
practice and related research.  
 
However, in the absence of a curative treatment, management of KBS, requires a multi-
disciplinary approach, which focuses on promoting timely healthcare access, specialist 
referral and providing appropriate assistance to facilitate ketamine abstinence.  
 
What is known about this topic 
 Habitual, recreational ketamine use can result in significant, irreversible damage to 
the bladder and urinary tract, causing a range of obstinate problems, including 
urinary incontinence and pain. Ketamine cessation may help to reduce bladder 
damage and reverse symptoms in some patients. 
 
What this paper adds 
 Initial KBS symptoms are normalised due to their progressive nature and 
commonality amongst other ketamine users, which results in delayed help seeking, 
exacerbates disease progression and further complicates patient management. 
 While ketamine cessation is essential, due to tolerance, dependence and pain 
management issues, users are unlikely to achieve this alone and will therefore 
require further specialist support to abstain. 
 Given the association with poly-drug dependence, chronic bladder problems and 
other related co-morbidities, KBS should be regarded as a core component of a more 
complex whole, the management of which requires an integrated, multi-disciplinary 
approach. 
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